
Saalex, AeroVironment help NASA get to Mars with morning Perseverance launch

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Teledyne stock climbs as Q2 earnings beat analyst estimates

Second-quarter sales for Thousand Oaks-based Teledyne Technologies dipped 5 percent to $743.3 million, and net income beat analyst estimates, sending the stock up 2.5 percent in early trading. Net income fell around 10 percent compared to the previous year’s second quarter to $93.7 million, or $2.48 per share, squarely beating analyst predictions of around $2 Read More →
Read More →Amgen puts $421M into BeiGene

Thousand Oaks biotech giant Amgen has upped its investment in Chinese oncology research firm BeiGene by $421 million. Amgen’s new investment, announced July 13, will allow the company maintain its ownership interest in BeiGene at 20.3 percent following a direct offering by the Chinese firm. Amgen shares rose more than 1 percent following the news Read More →
Read More →
Mindbody’s Stollmeyer to be executive chair of the board

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →
Judge upholds Amgen’s Enbrel patents

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →